New Approaches to Measuring Value in Oncology Therapy
Although clinical trial data have quantified patient survival gains associated with tyrosine kinase inhibitors in chronic myeloid leukemia, the overall value of these benefits is unknown.
Advertisement
Advertisement
Trending on AJMC
1
House Republicans Block Vote on ACA Subsidy Extension
2
Zasocitinib Hits Phase 3 End Points in Plaque Psoriasis
3
FDA Approval of Subcutaneous Amivantamab Offers Faster, Safer Option for EGFR-Mutated NSCLC
4
Study Suggests Adding BTKi to Chemo May Improve Early Outcomes in Richter Transformation in CLL
5
